Subscribe To
TCRR / Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
TCRR News
By InvestorPlace
March 6, 2023
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
TCR2 Therapeutics (NASDAQ: TCRR ) stock is jumping more than 30% in early trading on March 6 after the company agreed to merge with Adaptimmune (NASDA more_horizontal
By Seeking Alpha
February 15, 2023
TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path
Reprioritization of pipeline sees 40% reduction of workforce with enough cash to fund pipeline into early 2025. Proof of concept established using gav more_horizontal
By GlobeNewsWire
November 23, 2022
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of no more_horizontal